BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SAB Biotherapeutics (SABS)SAB BiotherapeuticsEarnings

MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its second quarter 2026

Related news

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

INMBINmune Bio2026-07-31 11:00 EST

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

XFORX4 Pharmaceuticals2026-08-06 20:15 EST

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

ACRSAclaris Therapeutics2026-08-06 10:59 EST

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

View all latest news

SAB Biotherapeutics

Fully Human Polyclonal Antibodies SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies. SAB-142 SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes. SAFEGUARD The registrational...

Recent company news

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Stock data

Close
3.85 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States